10-K: Inspire Veterinary Partners Reports $14.3 Million Net Loss in 2024, Cites Going Concern Uncertainty
Sentiment:
Annual Results
Inspire Veterinary Partners' 2024 annual report reveals a $14.3 million net loss and raises concerns about the company's ability to continue as a going concern.
Delay expectedPurchasing real estate with hospital acquisitions brings additional complexity and cost which can cause delays with the purchase of acquisitions and increase the costs of acquiring target locations.
Capital raiseThe company's ability to continue as a going concern is contingent upon its ability to obtain additional financing.The company will continue to seek to raise additional funding through debt or equity financing during the next twelve months.On March 25, 2025, Inspire Veterinary Partners (the Company) entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor in a registered direct offering (the Offering) 207,896 shares (the Shares) of Class A Common Stock (the Common Stock), pre-funded warrants (the Pre-Funded Warrants) to purchase up to 885,000 shares of Common Stock, five-year warrants (the Series A Warrants) to purchase up to 1,092,896 shares of Common Stock and eighteen-month warrants (the Series B Warrants and, together with the Series A Warrants, the Common Warrants) to purchase up to 1,092,896 shares of Common Stock.
Worse than expectedThe company reported a net loss of $14.3 million and has an accumulated deficit of $36.4 million, raising concerns about its financial stability.The company's auditor has expressed substantial doubt about its ability to continue as a going concern.The company's general and administrative expenses have increased significantly.
Summary
- Inspire Veterinary Partners reported a net loss of $14.3 million for the year ended December 31, 2024, compared to a $14.8 million net loss in the previous year.
- The company's accumulated deficit as of December 31, 2024, was $36.4 million.
- The report expresses substantial doubt about the company's ability to continue as a going concern, contingent upon obtaining additional financing and generating sufficient cash flow.
- Revenue remained relatively flat at $16.6 million, with a slight decrease compared to $16.7 million in 2023.
- The company divested Kauai Veterinary Clinic (KVC) in September 2024 for $2.0 million in notes payable, resulting in a gain of $467,049.
- General and administrative expenses increased by 18% to $11.4 million.
- The company is pursuing strategies to acquire additional veterinary hospitals and expand service offerings.
- The company is addressing material weaknesses in internal control over financial reporting.
- The company is subject to a Mandatory Panel Monitor for a period of one year, until December 12, 2025.
Sentiment
Score: 3
Explanation: The document presents a concerning financial situation with a significant net loss, accumulated deficit, and doubts about the company's ability to continue as a going concern. While there are some positive aspects, the overall tone is negative due to the financial instability and risks highlighted.
Positives
- The company completed the divestiture of Kauai Veterinary Clinic (KVC) for $2.0 million, resulting in a gain of $467,049.
- The company is pursuing strategies to acquire additional veterinary hospitals and expand service offerings, including equine and emergency care.
- The company is working to address material weaknesses in internal control over financial reporting.
- The company has a decentralized leadership team, allowing for acquisitions across the United States.
Negatives
- The company reported a net loss of $14.3 million for the year ended December 31, 2024.
- The company's accumulated deficit as of December 31, 2024, was $36.4 million.
- The report expresses substantial doubt about the company's ability to continue as a going concern.
- General and administrative expenses increased by 18% to $11.4 million.
- The company is subject to a Mandatory Panel Monitor for a period of one year, until December 12, 2025.
Risks
- The company's ability to continue as a going concern is contingent upon obtaining additional financing and generating sufficient cash flow.
- Failure to maintain effective internal controls over financial reporting could have a material adverse effect on the company's business, operating results, and stock price.
- The company may experience difficulties recruiting and retaining skilled veterinarians due to shortages.
- The trading price of the company's Class A common stock is volatile, which could result in substantial losses to investors.
- The company has received a listing deficiency notice from Nasdaq regarding its Class A Common Stock.
- The company is subject to a Mandatory Panel Monitor for a period of one year, until December 12, 2025.
Future Outlook
The company plans to expand through acquisitions of existing veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. The company expects to target a ten-unit per year acquisition pipeline with the five-year goal to acquire 50 locations throughout the United States.
Management Comments
- Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.
Industry Context
The veterinary industry is highly fragmented, with approximately 13 national consolidators and 30 regional consolidators owning or operating around 6,000 of the nearly 30,000 veterinary hospitals in the United States. Competitors range in size from large corporations like Mars and NVA to smaller regional groups. Growth in recent years has centered primarily on mid-sized and small platforms coming into the industry and/or acquiring existing hospitals in order to achieve location numbers between 50 and 200 units.
Comparison to Industry Standards
- The company aims to derive 70% to 80% of its gross revenue from services, aligning with industry targets.
- Competitors such as Mars and NVA own approximately 4,000 hospitals, while other national and regional groups such as Pathway/Thrive, VetcCor, Southern Vet Partners, Community Veterinary Partners, and others own less than 100 individual hospitals.
- The company differentiates itself through a broad equity offering to employees, a personalized approach to acquisitions, and a coaching-based workflow.
Legal Proceedings
- The Company is addressing a situation where a former animal clinic and hospital violated their non-compete agreement post-employment. Legal action has been initiated in Ohio State Court against the former owner, with efforts underway to fulfill court requirements for service.
Related Party Transactions
- The company entered into a consulting agreement with Blue Heron Consulting, where the company's director and Chief Operating Officer Charles Stith Keiser is the Chief Executive Officer.
- The company entered into a consulting agreement with Star Circle Advisory Group, LLC, where Kimball Carr, Chief Executive Officer (CEO), Peter Lau, former Interim Chief Financial Officer and Director, James Coleman, Director, and Richard Marten, Director are owners.
- On September 20, 2024, KVC sold Kauai Veterinary Clinic (KVC) to Kauai RE Holdings LLC. The agent for the sale was Gregory Armstrong, a current shareholder of the Company and a member of Kauai RE. Charles Keiser, DVM, is a member of Kauai RE and the father of our board member Charles Stith Keiser, who is the Companys largest shareholder through his entity Wilderness Trace Veterinary Partners, LLC.
Stakeholder Impact
- Shareholders face the risk of substantial losses due to the volatile stock price and the company's financial instability.
- Employees may be affected by potential cost-cutting measures or restructuring due to the company's financial challenges.
- Customers may experience changes in service quality or availability if the company faces financial difficulties.
Next Steps
- The company will continue to seek to raise additional funding through debt or equity financing during the next twelve months.
- The company intends to continue to conduct the due diligence necessary to strategically acquire existing general practices, specialty hospitals, and/or expand existing locations to include emergency care and more complex surgeries, holistic care and comprehensive diagnostics which allow it to offer more complex surgeries and internal medicine work ups.
Key Dates
| Date | Description |
|---|---|
| 2020-12-02 | Inspire Veterinary Partners, Inc. incorporated in Delaware |
| 2021-01-11 | Company entered into three separate commercial loans with First Southern National Bank (FSB) as part of the acquisition. |
| 2021-06-25 | Company entered into a master line of credit loan agreement (MLOCA) with Wealth South a division of Farmers National Bank of Danville, Kentucky (FNBD). |
| 2022-06-29 | The Company converted into a Nevada C-corporation |
| 2022-08-18 | The MLOCA was amended and restated to terminate the revolving feature on the Revolving Line and convert the line of credit to a closed end draw note (Closed End Draw Note) that mature on August 18, 2024. |
| 2022-10-18 | Effective October 18, 2022, the Board of Directors of Inspire Veterinary Partners adopted the 2022 Equity Incentive Plan, (the 2022 Plan). |
| 2022-10-31 | The company entered into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. |
| 2022-11-15 | The Company amended the consulting agreement with Alchemy Advisory, LLC until June 30, 2023. |
| 2022-11-18 | On November 18, 2022, the Company entered into an Original Issue Discount Secured Convertible Note loan (bridge loan) with Target Capital 1, LLC for $1,136,364. |
| 2022-12-16 | On December 16, 2022, the company entered into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. |
| 2023-05-30 | On May 30, 2023, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $1,050,000 with an unrelated third-party financial institution. |
| 2023-06-30 | On June 30, 2023, the Company amended its articles of incorporation by the filing of a certificate of designation for the Series A preferred stock. |
| 2023-08-31 | On August 31, 2023, we closed our IPO of 640 shares of class A common stock, at a public price of $1,000.00 per share. |
| 2023-11-07 | On November 7, 2023, the Company amended its article of incorporation to increase the total authorized preferred stock by 2,000,000 shares. |
| 2023-11-08 | On November 8, 2023, the Company entered into a commercial loan with FSB as part of the Valley Vet practice acquisition. |
| 2023-11-30 | On November 30, 2023, the Company entered into a common stock purchase agreement with a 3rd party investor (the Investor), to which the investor committed to purchase up to $30 million of the Companys Class A common stock. |
| 2023-12-16 | On December 16, 2024, we received a staff determination from Nasdaq to delist the Companys securities from the Nasdaq Capital Market, based upon the closing bid price of the Companys Class A Common Stock. |
| 2024-01-01 | The board of directors issued 500 warrants of Class A common stock issuable upon cashless exercise of a warrant granted to Kimball Carr, our CEO, in consideration for his personal guaranty of the Company loans. |
| 2024-01-18 | On January 18, 2024, the Company amended the financing arrangement to borrow an additional $549,185 resulting in the weekly payments to increase to $86,214 to be paid over 43 weeks. |
| 2024-02-14 | On February 14, 2024, the Company issued 486 shares of Class A Common stock to an Investor. |
| 2024-03-26 | On March 26, 2024, Inspire entered into a securities purchase agreement (the Purchase Agreement) with a certain investor. |
| 2024-04-04 | On April 4, 2024, the Company entered into a new financing agreement for gross proceeds of $420,000 with a different unrelated third-party financial institution. |
| 2024-05-07 | On May 7, 2024, the Company amended the financing arrangement to borrow an additional $518,750 resulting in the weekly payments to increase to $90,229 to be paid over 48 weeks. |
| 2024-05-08 | On May 8, 2024, the Company effected a 100-for-1 reverse stock split (Reverse Split) of the Companys authorized and outstanding shares of Class A common stock. |
| 2024-06-11 | On June 11, 2024, Inspire entered into a securities purchase agreement (the Purchase Agreement) with two investors. |
| 2024-09-20 | On September 20, 2024, the Company completed the divestiture of its Kauai Veterinary Clinic (KVC) to Kauai RE Holdings LLC for $2.0 million, in notes payable assumed by the buyer, with no cash consideration. |
| 2024-12-12 | On December 12, 2024, the Company received a letter from the Staff notifying the Company that it has demonstrated compliance with the with the minimum equity requirement in Listing Rule 5550(b)(1) as required by the Panel. |
| 2024-12-24 | On December 24, 2024, the Company amended the financing arrangement to borrow an additional $513,650 resulting in the weekly payments to increase to $71,995 to be paid over 41 weeks. |
| 2025-01-27 | On January 27, 2025, the Company effected a 25-for-1 reverse stock split (Reverse Split) of the Companys authorized and outstanding shares of Class A common stock. |
| 2025-03-25 | On March 25, 2025, Inspire Veterinary Partners (the Company) entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor in a registered direct offering (the Offering) 207,896 shares (the Shares) of Class A Common Stock (the Common Stock), pre-funded warrants (the Pre-Funded Warrants) to purchase up to 885,000 shares of Common Stock, five-year warrants (the Series A Warrants) to purchase up to 1,092,896 shares of Common Stock and eighteen-month warrants (the Series B Warrants and, together with the Series A Warrants, the Common Warrants) to purchase up to 1,092,896 shares of Common Stock. |
| 2025-03-31 | Date of report. |
Keywords
veterinary, acquisitions, hospitals, financial results, net loss, going concern, Inspire Veterinary Partners, stock split, Nasdaq, compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.